Compass Pathways (NASDAQ: CMPS) surges 7.47% on seventh Radial Health partnership for psychedelic medicine pipeline.

Compass Pathways (NASDAQ: CMPS) surged 7.4695% in pre-market trading on January 7, 2026, driven by strategic advancements in its psychedelic medicine pipeline.

The biotech firm announced a seventh collaboration with Radial Health, a national interventional psychiatry network, to develop scalable delivery models for its investigational COMP360 psilocybin treatment. This partnership builds on existing agreements with providers like Hackensack Meridian Health and Journey Clinical, underscoring Compass’s focus on integrating COMP360 into diverse U.S. healthcare systems if FDA-approved.

Radial’s expertise in virtual care and operational scalability aligns with Compass’s goal to streamline treatment accessibility for mental health conditions such as treatment-resistant depression and PTSD.

Recent developments include an Oppenheimer upgrade to “Outperform” with a $15 price target, citing COMP360’s potential to capture a $1.5 billion peak sales opportunity. Additionally, Compass bolstered its leadership by appointing Dr. Jeffrey Jonas, a neuroscience R&D veteran, to its board. These moves highlight the company’s strategic focus on advancing its psychedelic therapy platform amid ongoing phase 3 trials for TRD.

As Compass Pathways continues its clinical development and market expansion, the company is also actively monitoring regulatory timelines and market readiness for large-scale implementation of COMP360. The company’s stock performance and institutional support suggest a growing investor appetite for psychedelic-based therapeutics in the mental health sector, although long-term success will depend on the outcomes of its clinical trials and the broader regulatory environment.